Hefei Mandi's Magnetocardiograph, 4 and 5 August 2026: Two Unresolved Deployment Descriptions in Chinanews and Xinhua

Quentir Medicine Monitor

Evidence-based insights for quantum medicine.

On 4 August 2026 a state press tour called Vibrant China Field Study visited the Institute of Health and Medicine at the Hefei Comprehensive National Science Center and watched a magnetocardiograph acquire signal in the laboratory of Hefei Mandi Medical Technology. Two reports came out of that visit on consecutive days, both from official Chinese outlets, both describing the same machine, and they describe its stage of deployment in different words that no public source resolves.

The company builds a magnetocardiograph around a superconducting quantum interference device, the detector class that reads magnetic fields at the femtotesla scale, and a 2022 industry profile says it obtained an NMPA registration in 2019. The 4 August report describes the machine as working with ten key hospitals in scientific research collaboration and entering a pre-mass-production stage. The 5 August report describes it as installed and in use at more than ten key hospitals in deployed application, with the company's production lines running at full load. A hospital deciding whether to buy one needs to know which of those two sentences is the current state of the product.